

Public Interest Incorporated Foundation
The NOVARTIS Foundation (Japan) for the Promotion of Science
Business Report & Financial Statements

Fiscal 2024 (38th fiscal year) (April 1, 2024 - March 31, 2025)

The Foundation was established on September 4, 1987, with the approval of the Minister of Education and Culture and was converted to a public interest foundation on April 1, 2012 with the approval of the Cabinet Office. Since its establishment, the Foundation has been providing public service to the public, and the current status of its operations, general affairs and accounts for fiscal year 2024 (the 38th fiscal year) are as follows

I. Business Situations

1. The 38th Novartis Research Grant

The purpose of the grant is to support creative research conducted in Japan in the fields of biological and life sciences and related chemistry and information science. We requested nominations from 628 persons, including the heads of national, public and private universities, research institutes and affiliated hospitals, as well as trustees and councilors of the Foundation, and received 261 nominations. The Selection Committee selected 36 candidates (plus two runners-up), and the Board of Trustees made the decision. A total of 36 million yen was awarded in April-May 2025, with each award amounting to 1 million yen. The ratio of adoption was 7.3 times.

2. Research Meeting Grant

The purpose of the grant is to support research meetings of international interest held in Japan in the fields of biological and life sciences and related chemistry and information science.

FY2024 Meeting: Five candidates (one runner-up) were selected by the Selection Committee from 23 applications, and the decision was made by the Board of Trustees (adoption ratio: 4.6 times). The recipients received 400,000 yen each, for a total of 2 million yen, in April 2025.

3. Annual Report Publication

We have prepared an annual report to expand our understanding of and support for foundation activities. The book of annual reports was distributed to the recipients of the FY2022 grant and also posted on the website. The annual reports include the report on the achievements of the FY2022 research grants recipients, the report on the 2022 research meetings, and the status of the foundation's activities.

II. General Affairs Overview

1. Trustees, Auditors, Councilors and Selection Committee members

The list of Trustees, Auditors, Councilors and Selection Committee members as of December 1, 2024 is on a separate page.

2. Meetings of the Foundation (Board Meeting of Trustees, Board Meeting of Councilors and Grant Selection Committee)

1) 35th Board of Trustees Meeting (May 22, 2024) at Tokyo Kaikan Main Bldg “Azalea”

Number of Trustees 5 (Quorum: 3): Attendees: 5 Directors, 2 Auditors

Proposal 1: Business Report and Settlement of Accounts for FY2023 (Approval of the original proposal)

Proposal 2: Resignation and appointment of selection committee members for FY2024 (Resolved and approved)

Proposal 3: Confirm the application guidelines for Novartis Research Grant and Research Meetings for FY2024

Proposal 4: Convening of the 16th Meeting of the Board of Councilors (Approval of the original proposal)

1) Matters to be reported: Report on the execution of duties by the Representative Trustee, and status report on the results and achievements of the Research Grants and Research Meetings

2) 17th Meeting of the Board of Councilors (June 19, 2024) at AP Shimbashi “Room J”

Number of Councilors: 10 (Quorum: 6): 10 Councilors in attendance

Proposal 1: Election of Signatories to the Minutes (Approval of the original proposal)

Proposal 2: Business Report and Settlement of Accounts for FY2024 (Approval of the original proposal)

Proposal 3: Election of 10 Councilors (Approval of the original proposal)

Proposal 4: Election of 5 Trustees (Approval of the original proposal)

Proposal 5: Election of 2 Auditors (Approval of the original proposal)

Report: Business Plan and Budget for FY2024 • Retirement and election of selection committee members; • The Application Guidelines for the 38th Novartis Research Grants and Research Meeting, -Publication Status of the FY2020-FY2022 Novartis Research Grants,

3) 36th Board of Trustees Meeting (June 19, 2024) Deemed Resolution

Proposal : Election of Chairman of the Board of Trustees (All 5 trustees agree, and all 2 auditors express no objection)

4) 37th Board of Trustees Meeting (November 7, 2024) Deemed Resolution

Proposal 1: To hold the 18th meeting of the Board of Councilors and under the deemed resolution procedure

Proposal 2: That the election of a member of the Board of Trustees shall be an agenda item for the 18th meeting of the Board of Councilors. (All 5 trustees agree, and all 2 auditors express no objection)

5) 18th Meeting of the Board of Councilors (November 14, 2024) Deemed Resolution

Proposal: Election of 1 Trustee (John Paul Pullicino) (All 10 councilors agree)

6) 13th Selection Committee Meeting (December 13, 2024) at AP Shimbashi “Room J”

Number of Selection Committee members: 20 (Quorum: 11): 16 members in attendance

Agenda 1: Selection of the 38th Novartis Research Grants for FY2024 (36 grants and 2 alternates were selected)

Agenda 2: Selection of Research Meeting Grants for FY 2024 (5 grants and 1 runner-up selected)

7) 38th Board of Trustees Meeting (February 14, 2025) at Daiichi Hotel Tokyo “Cosmos”

Number of Trustees 5 (Quorum: 3): Attendees: 5 Trustees, 2 Auditors

Proposal 1: Determination of recipients of the 38th Novartis Research Grants and Meeting Grants for FY2024 (Approval of the original proposal)

Proposal 2: Business plan and budget for FY2025 (Approval of original proposal)

Proposal 3: Renewal of the designated institutions of the Novartis Research Grants for FY2025 (Approval of the original proposal)

Proposal 4: Election Policy for Selection Committee Members for FY2025

Proposal 5: To enact the Personal Information Protection Regulations and the Specific Personal Information Protection Regulations

Proposal 6: Revision of the regulation on food and beverage

Report: Report on the status of execution of duties by Representative Trustee.

3. Matters related to donations

The Foundation received a general donation of 40 million yen from Novartis Pharma K.K., for a total of 40 million yen.

III. Financial statement (FY 2024)

Ordinary income includes 13.21 million yen and 0.69 million yen from the management of basic assets and other assets, respectively, and 40 million yen from donations, for a total ordinary income of 53.90 million yen.

49.91million yen in operating expenses and 5.39 million yen in administrative expenses.

The total ordinary expenses were 55.31 million yen.

Operating expenses accounted for 90.2% of recurring expenses, and subsidies of 38 million yen accounted for 76.1% of operating expenses.

Total net assets for the period totaled 1,167.62 million yen, a decrease of 1.40 million yen from the previous period.

The Foundation did not raise any funds (borrowing) in FY2024.

In terms of capital investment, 1.49 million yen in outsourcing expenses for the Foundation's website relocation cost. (we expect 1 million yen in FY2025 outsourcing expenses for the relocation cost).